Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Exscientia's GenAI platform receive an industry award or recognition by mid-2025?
Yes • 50%
No • 50%
Industry award announcements, press releases, or official Exscientia communications
Exscientia Launches AWS-Powered GenAI Platform for Drug Discovery
Jul 10, 2024, 11:13 AM
Exscientia has launched a state-of-the-art GenAI platform to advance drug discovery, built using AWS technology. The platform integrates generative AI drug design and robotic lab automation to accelerate the delivery of high-quality drugs at faster speeds and lower costs. This development signifies a significant shift in the drug discovery landscape, leveraging massive proprietary datasets and AI to produce intelligence that leads to drug production. Jensen Huang highlighted the scale of data and compute reaching an inflection point in this field.
View original story
Best AI Startup • 25%
Best Architectural Innovation • 25%
Best Use of AI in Design • 25%
Other • 25%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Nobel Prize • 25%
Lasker Award • 25%
Breakthrough Prize • 25%
Other • 25%
Yes • 50%
No • 50%
Insilico Medicine • 25%
Amgen • 25%
Terray Therapeutics • 25%
Other • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
2-3 years • 25%
More than 3 years • 25%
Less than 1 year • 25%
1-2 years • 25%
4-5 companies • 25%
0-1 companies • 25%
More than 5 companies • 25%
2-3 companies • 25%